GSK to acquire AZ Tika
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline plans to acquire Sweden's leading OTC analgesic treatment, Alvedon, as part of a deal to buy AZ Tika from AstraZeneca for 146 million U.K. pounds ($219 million), the U.K.-based firm announces Nov. 20. AZ Tika's portfolio also includes Minifom, for GI disorders, and the decongestants Nezeril and Nasin, all of which are sold predominantly in Sweden and the Nordic region. The product portfolio's net sales reached about $40.5 million in 2007
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.